177Lu-LNC5001

N/A

Report date: 2025/11/14 09:32:49

NME

Base Information

Drug Name177Lu-LNC5001

Drug Alias Name177Lu-LNC5001177Lu-LNC-5001

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesYantai Lannacheng Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesYantai Lannacheng Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A